U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Relapsed/refractory diffuse large B-cell lymphoma

MedGen UID:
208957
•Concept ID:
C0855112
•
Neoplastic Process
Synonyms: Diffuse Large B-Cell Lymphoma Refractory; Refractory Diffuse Large B-Cell Lymphoma; relapsed/refractory diffuse large B-cell lymphoma
 
Monarch Initiative: MONDO:0000901

Definition

Diffuse large B-cell lymphoma that is resistant to treatment. [from NCI]

Professional guidelines

PubMed

ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma.
Alderuccio JP, Sharman JP
Blood Rev 2022 Nov;56:100967. Epub 2022 Apr 22 doi: 10.1016/j.blre.2022.100967. PMID: 35489963
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).
Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, Corbacioglu S, Duarte RF, Einsele H, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Robinson S, Saccardi R, Sanchez-Guijo F, Snowden JA, Srour M, Styczynski J, Urbano-Ispizua A, Hayden PJ, Kröger N
Haematologica 2020;105(2):297-316. Epub 2020 Jan 31 doi: 10.3324/haematol.2019.229781. PMID: 31753925Free PMC Article
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group.
Ng AK, Yahalom J, Goda JS, Constine LS, Pinnix CC, Kelsey CR, Hoppe B, Oguchi M, Suh CO, Wirth A, Qi S, Davies A, Moskowitz CH, Laskar S, Li Y, Mauch PM, Specht L, Illidge T
Int J Radiat Oncol Biol Phys 2018 Mar 1;100(3):652-669. doi: 10.1016/j.ijrobp.2017.12.005. PMID: 29413279

Recent clinical studies

Etiology

Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Duell J, Abrisqueta P, Andre M, Gaidano G, Gonzales-Barca E, Jurczak W, Kalakonda N, Liberati AM, Maddocks KJ, Menne T, Nagy Z, Tournilhac O, Kuffer C, Bakuli A, Amin A, Gurbanov K, Salles G
Haematologica 2024 Feb 1;109(2):553-566. doi: 10.3324/haematol.2023.283480. PMID: 37646664Free PMC Article
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Sabatelli L, Waltl EE, Winderlich M, Sporchia A, Kurukulasuriya NC, Cordoba R, Hess G, Salles G
Ann Hematol 2023 Jul;102(7):1773-1787. Epub 2023 May 12 doi: 10.1007/s00277-023-05196-4. PMID: 37171597Free PMC Article
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Duell J, Maddocks KJ, González-Barca E, Jurczak W, Liberati AM, De Vos S, Nagy Z, Obr A, Gaidano G, Abrisqueta P, Kalakonda N, André M, Dreyling M, Menne T, Tournilhac O, Augustin M, Rosenwald A, Dirnberger-Hertweck M, Weirather J, Ambarkhane S, Salles G
Haematologica 2021 Sep 1;106(9):2417-2426. doi: 10.3324/haematol.2020.275958. PMID: 34196165Free PMC Article
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group.
Ng AK, Yahalom J, Goda JS, Constine LS, Pinnix CC, Kelsey CR, Hoppe B, Oguchi M, Suh CO, Wirth A, Qi S, Davies A, Moskowitz CH, Laskar S, Li Y, Mauch PM, Specht L, Illidge T
Int J Radiat Oncol Biol Phys 2018 Mar 1;100(3):652-669. doi: 10.1016/j.ijrobp.2017.12.005. PMID: 29413279
Relapsed/refractory diffuse large B-cell lymphoma.
Friedberg JW
Hematology Am Soc Hematol Educ Program 2011;2011:498-505. doi: 10.1182/asheducation-2011.1.498. PMID: 22160081

Diagnosis

Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
Vodicka P, Benesova K, Janikova A, Prochazka V, Belada D, Mocikova H, Steinerova K, Duras J, Karban J, Hanackova V, Sykorova A, Obr A, Trneny M
Eur J Haematol 2022 Aug;109(2):162-165. Epub 2022 May 11 doi: 10.1111/ejh.13784. PMID: 35502609
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Duell J, Maddocks KJ, González-Barca E, Jurczak W, Liberati AM, De Vos S, Nagy Z, Obr A, Gaidano G, Abrisqueta P, Kalakonda N, André M, Dreyling M, Menne T, Tournilhac O, Augustin M, Rosenwald A, Dirnberger-Hertweck M, Weirather J, Ambarkhane S, Salles G
Haematologica 2021 Sep 1;106(9):2417-2426. doi: 10.3324/haematol.2020.275958. PMID: 34196165Free PMC Article
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D'Aveni-Piney M, Obéric L, Bodet-Milin C, Bories P, Olivier P, Lafon I, Berriolo-Riedinger A, Galli E, Bernard S, Rubio MT, Bossard C, Meignin V, Merlet P, Feugier P, Le Gouill S, Ysebaert L, Casasnovas O, Meignan M, Chevret S, Thieblemont C
Blood Adv 2020 Nov 24;4(22):5607-5615. doi: 10.1182/bloodadvances.2020003001. PMID: 33180899Free PMC Article
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group.
Ng AK, Yahalom J, Goda JS, Constine LS, Pinnix CC, Kelsey CR, Hoppe B, Oguchi M, Suh CO, Wirth A, Qi S, Davies A, Moskowitz CH, Laskar S, Li Y, Mauch PM, Specht L, Illidge T
Int J Radiat Oncol Biol Phys 2018 Mar 1;100(3):652-669. doi: 10.1016/j.ijrobp.2017.12.005. PMID: 29413279
Relapsed/refractory diffuse large B-cell lymphoma.
Friedberg JW
Hematology Am Soc Hematol Educ Program 2011;2011:498-505. doi: 10.1182/asheducation-2011.1.498. PMID: 22160081

Therapy

Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Duell J, Abrisqueta P, Andre M, Gaidano G, Gonzales-Barca E, Jurczak W, Kalakonda N, Liberati AM, Maddocks KJ, Menne T, Nagy Z, Tournilhac O, Kuffer C, Bakuli A, Amin A, Gurbanov K, Salles G
Haematologica 2024 Feb 1;109(2):553-566. doi: 10.3324/haematol.2023.283480. PMID: 37646664Free PMC Article
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study.
Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Wang Y, Qin Y, Wang L, Xu ZC, Carlo-Stella C
Haematologica 2024 Apr 1;109(4):1184-1193. doi: 10.3324/haematol.2023.283459. PMID: 37646659Free PMC Article
Novel agents in relapsed/refractory diffuse large B-cell lymphoma.
Varma G, Goldstein J, Advani RH
Hematol Oncol 2023 Jun;41 Suppl 1:92-106. doi: 10.1002/hon.3143. PMID: 37294966
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Sabatelli L, Waltl EE, Winderlich M, Sporchia A, Kurukulasuriya NC, Cordoba R, Hess G, Salles G
Ann Hematol 2023 Jul;102(7):1773-1787. Epub 2023 May 12 doi: 10.1007/s00277-023-05196-4. PMID: 37171597Free PMC Article
Relapsed/refractory diffuse large B-cell lymphoma.
Friedberg JW
Hematology Am Soc Hematol Educ Program 2011;2011:498-505. doi: 10.1182/asheducation-2011.1.498. PMID: 22160081

Prognosis

Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol.
Eslami M, Mehrabi M, Payandeh M, Saba F
PLoS One 2024;19(8):e0308247. Epub 2024 Aug 1 doi: 10.1371/journal.pone.0308247. PMID: 39088571Free PMC Article
Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.
Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, Yamamoto K, Fujisaki T, Ishitsuka K, Ishizawa K, Ikezoe T, Nishikori M, Akahane D, Fujita J, Dinh M, Soong D, Noguchi H, Buchbjerg JK, Favaro E, Fukuhara N
Cancer Sci 2023 Dec;114(12):4643-4653. Epub 2023 Nov 3 doi: 10.1111/cas.15996. PMID: 37921363Free PMC Article
Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Lin LH, Ghasemi M, Burke SM, Mavis CK, Nichols JR, Torka P, Mager DE, Hernandez-Ilizaliturri FJ, Goey AKL
Target Oncol 2023 Sep;18(5):685-695. Epub 2023 Aug 26 doi: 10.1007/s11523-023-00992-4. PMID: 37632592Free PMC Article
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
Belada D, Kopeckova K, Bergua Burgues JM, Stevens D, André M, Persona EP, Pichler P, Staber PB, Trneny M, Duell J, Waldron-Lynch M, Wagner S, Mukhopadhyay A, Dirnberger-Hertweck M, Burke JM, Nowakowski GS
Blood 2023 Oct 19;142(16):1348-1358. doi: 10.1182/blood.2023020637. PMID: 37369099Free PMC Article
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D'Aveni-Piney M, Obéric L, Bodet-Milin C, Bories P, Olivier P, Lafon I, Berriolo-Riedinger A, Galli E, Bernard S, Rubio MT, Bossard C, Meignin V, Merlet P, Feugier P, Le Gouill S, Ysebaert L, Casasnovas O, Meignan M, Chevret S, Thieblemont C
Blood Adv 2020 Nov 24;4(22):5607-5615. doi: 10.1182/bloodadvances.2020003001. PMID: 33180899Free PMC Article

Clinical prediction guides

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis.
Kim J, Cho J, Lee MH, Yoon SE, Kim WS, Kim SJ
Blood 2024 Aug 8;144(6):629-638. doi: 10.1182/blood.2023023419. PMID: 38696731
Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.
Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, Yamamoto K, Fujisaki T, Ishitsuka K, Ishizawa K, Ikezoe T, Nishikori M, Akahane D, Fujita J, Dinh M, Soong D, Noguchi H, Buchbjerg JK, Favaro E, Fukuhara N
Cancer Sci 2023 Dec;114(12):4643-4653. Epub 2023 Nov 3 doi: 10.1111/cas.15996. PMID: 37921363Free PMC Article
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Sabatelli L, Waltl EE, Winderlich M, Sporchia A, Kurukulasuriya NC, Cordoba R, Hess G, Salles G
Ann Hematol 2023 Jul;102(7):1773-1787. Epub 2023 May 12 doi: 10.1007/s00277-023-05196-4. PMID: 37171597Free PMC Article
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D'Aveni-Piney M, Obéric L, Bodet-Milin C, Bories P, Olivier P, Lafon I, Berriolo-Riedinger A, Galli E, Bernard S, Rubio MT, Bossard C, Meignin V, Merlet P, Feugier P, Le Gouill S, Ysebaert L, Casasnovas O, Meignan M, Chevret S, Thieblemont C
Blood Adv 2020 Nov 24;4(22):5607-5615. doi: 10.1182/bloodadvances.2020003001. PMID: 33180899Free PMC Article
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.
Awasthi R, Pacaud L, Waldron E, Tam CS, Jäger U, Borchmann P, Jaglowski S, Foley SR, van Besien K, Wagner-Johnston ND, Kersten MJ, Schuster SJ, Salles G, Maziarz RT, Anak Ö, Del Corral C, Chu J, Gershgorin I, Pruteanu-Malinici I, Chakraborty A, Mueller KT, Waller EK
Blood Adv 2020 Feb 11;4(3):560-572. doi: 10.1182/bloodadvances.2019000525. PMID: 32045475Free PMC Article

Recent systematic reviews

Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma.
Miller SD, Lozano-Ortega G, Mutebi A, Briggs O, Sail K, Elliott B, Kalsekar A
J Comp Eff Res 2023 Jan;12(1):e220146. Epub 2022 Nov 23 doi: 10.2217/cer-2022-0146. PMID: 36417238Free PMC Article
Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: A systematic review.
Tian L, Li C, Sun J, Zhai Y, Wang J, Liu S, Jiang Y, Wu W, Xing D, Lv Y, Guo J, Xu H, Sun H, Li Y, Li L, Zhao Z
Front Immunol 2022;13:1041177. Epub 2023 Jan 17 doi: 10.3389/fimmu.2022.1041177. PMID: 36733398Free PMC Article
A text-mining tool generated title-abstract screening workload savings: performance evaluation versus single-human screening.
Carey N, Harte M, Mc Cullagh L
J Clin Epidemiol 2022 Sep;149:53-59. Epub 2022 May 30 doi: 10.1016/j.jclinepi.2022.05.017. PMID: 35654270
Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review.
Colosia A, Njue A, Trask PC, Olivares R, Khan S, Abbe A, Police R, Wang J, Ruiz-Soto R, Kaye JA, Awan F
Clin Lymphoma Myeloma Leuk 2014 Oct;14(5):343-355.e6. Epub 2014 Mar 1 doi: 10.1016/j.clml.2014.02.012. PMID: 24768510

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...